2 recruiting, 1 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Completed 1 |
Follow Gliknik Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia GL-2045 - Immune Thrombocytopenia | Phase 1 | Recruiting | Gliknik Inc. | 42 | 2026-04-14 | 2026-05-26 |
| Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease GL-0719, Placebo - First in Man Study to Evaluate Initial Safety | Phase 1 | Recruiting | Gliknik Inc. | 70 | 2022-04-08 | 2026-03-06 |
| Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity GL-0817, Hiltonol, Sargramostim - Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | Completed | Gliknik Inc. | 80 | 2017-03-30 | 2022-03-08 |
Purpura, Thrombocytopenic, Idiopathic (1) · Squamous Cell Carcinoma of Head and Neck (1)
Cyclophosphamide (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · poly ICLC (1) · sargramostim (1)
United Kingdom (2) · Hungary (1) · Poland (1) · Russia (1) · Serbia (1) · Spain (1) · Ukraine (1) · United States (1)
2016 (1), 2025 (1)